Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Vera Therapeutics' management team will present at the TD Cowen Immunology & Inflammation Summit (Nov. 12-13, 2025).
-
Vera Therapeutics Submits BLA to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgAN
-
Vera Therapeutics today reported its business highlights and financial results for the third quarter ended September 30, 2025
-
Vera Therapeutics to host an investor call and Webcast to provide an ORIGIN 3 update on November 6, 2025 at 4:30 pm ET.
-
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
-
SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative...